Navigation Links
Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease
Date:11/9/2010

o us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on w
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston College physics professor Willie Padilla receives PECASE award
2. Stryker Announces Definitive Agreement to Acquire the Neurovascular Division of Boston Scientific for $1.5 Billion
3. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
4. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
5. Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
6. A Year Since Obamas Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward
7. GenomeQuest Announces Boston Seminar: Sequence Data Management for Next Generation Sequencing
8. Caturano and Company to Host Boston Biotech Event, "BIBA Biotech 2010 and Beyond"
9. UMass Boston's Venture Development Center Announces New Bio-Science Partner
10. Molecular Genetics Core Facility at Childrens Hospital Boston Selects HybSelect from febit for Targeted Resequencing
11. Boston Scientific Announces Completion of $2 Billion Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Nearly 20,000 medical professionals and healthcare leaders ... Clinical Lab Expo in Chicago ... diagnostic research and technology that will advance medicine and ... of Wednesday, July 30, more than 19,500 attendees had ... Lab Expo, with more than 10,000 of these attendees ...
(Date:7/31/2014)... the sound-processing part of the mouse brain in a ... trees in view. Their imaging technique allows zooming in ... and it enabled the team to watch brain cells ... results, which represent a step toward better understanding how ... the journal Neuron . , In the past, ...
(Date:7/31/2014)... Calif. , July 31, 2014 Rogne ... San Francisco Bay Area , has acquired a ... of Oxford,s commercialisation company. The potent anti-inflammatory activity of ... at the University of Oxford,s Sir William ... company, which has raised over $1.5 million in seed ...
(Date:7/31/2014)... 2014 Research and Markets has ... 2014-2018" report to their offering. ... study of the genetic material or genomes of an ... for the discovery and development of diagnostic and therapeutic ... conditions. Genomics is supported by three major product segments: ...
Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... BOULDER, Colo., and IPSWICH, Mass., July 27, ... Biolabs, Inc. (NEB) announce today that they ... whereby SomaLogic will provide specific SOMAmers as ... and future NEB nucleic acid amplification and ...
... July 27, 2011 Cadence Pharmaceuticals, Inc. (NASDAQ: ... and commercializing proprietary products principally for use in the hospital ... ended June 30, 2011 financial results on Wednesday, August 3, ... call and live webcast to discuss the financial results on ...
... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today ... registration trial of KRX-0401 (perifosine) for the treatment of ... over 430 randomized patients, is being conducted pursuant to ... Drug Administration (FDA) and with Fast-Track Designation.  Perifosine is ...
Cached Biology Technology:Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 4Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 5
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... experimental vaccine protected 100 percent of animal models against ... , which causes an intestinal disease that kills approximately ... print in Infection and Immunity . , ... non-human primates against the purified toxins produced by ... spore infection, a laboratory model that mimics the human ...
(Date:7/31/2014)... BOZEMAN, Mont. In the same week that the ... dangers of skin cancer, researchers at Montana State University ... the genetic code in every cell responds ... advance fundamental understanding of DNA damage by the UV ... skin cancer, aging and some degenerative eye diseases. ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3
... The effects of fruit and vegetable consumption on ... origin, according to a new study published in the ... Dietetic Association . Researchers found that within the proximal ... and broccoli) were associated with decreased risk of these ...
... instinctive but is a skill that birds learn from ... Weaver birds in Botswana as they built multiple nests ... contrast with the commonly-held assumption among scientists that nest-building ... individual birds varied their technique from one nest to ...
... time discovered sixteen new sections of the genetic code that ... for better prevention as well as treatment for lung diseases. ... in Europe, the USA and Australia identified genetic variants associated ... sheds new light on the molecular basis of lung diseases ...
Cached Biology News:Fruits and vegetables reduce risks of specific types of colorectal cancers 2New discoveries in genetics of lung health 2
... contains sufficient materials for 1,464 array sample elements. ... , Blocker BSA in PBS (10X): ... HRP-conjugated: 10 g , BupH Phosphate ... Tween-20: 2 x 10 ml ampules , SuperSignal ...
... The Partec Cell Counter Analyser counts ... that the CCA detects only cells, so ... influence the results.,While passing through a 250 ... a fluorescence light signal which is used ...
... system, 100-120 V, is used for biolistic ... handheld device employs an adjustable helium pulse ... gold microcarriers from the inner wall of ... cells. This system has a 2 square-centimeter ...
... Results Laser Capture Microdissection (LCM) enables ... accuracy of molecular assays by starting with ... structures isolated from whole tissue or cytology ... 1996 at the National Institutes of Health ...
Biology Products: